Rznomics is developing safe and effective biopharmaceuticals in oncology, degenerative disease, and genetic disease based on RNA platform technology called trans-splicing ribozyme. Acknowledged by bio-focused institutions, Rznomics has raised \23.7 billion from series A& B and recently raised \37.2 billion from series C, resulting in a total of \60.9 billion of fundraising. Also, Rznomics received \8 billion for the new drug development research funding from the government.
In 2022 1H, Rznomics’ RZ-001 IND submission for the HCC treatment was approved by MFDS, and the clinical trial for the RZ-001 is currently running. In addition to the RZ-001, Rznomics has competitive and innovative pipelines, such as glioblastoma multiforme, Alzheimer’s disease, genetic ocular disease (retinitis pigmentosa), and circular RNA technology.
Rznomics is also actively partnering with global companies to discuss collaboration opportunities in co-research, co-development, and licensing.
In 2022 1H, Rznomics’ RZ-001 IND submission for the HCC treatment was approved by MFDS, and the clinical trial for the RZ-001 is currently running. In addition to the RZ-001, Rznomics has competitive and innovative pipelines, such as glioblastoma multiforme, Alzheimer’s disease, genetic ocular disease (retinitis pigmentosa), and circular RNA technology.
Rznomics is also actively partnering with global companies to discuss collaboration opportunities in co-research, co-development, and licensing.
Location: South Korea, Seongnam-si
Employees: 11-50
Founded date: 2017
Investors 6
| Date | Name | Website |
| 18.05.2023 | Synergy IB... | synergyib.... |
| 23.08.2025 | Yuanta Inv... | yuantainve... |
| - | Groom inve... | groominves... |
| - | SBI Invest... | sbik.co.kr |
| - | UTC Invest... | utc.co.kr |
| - | we venture... | en.weventu... |
Mentions in press and media 6
| Date | Title | Description |
| 07.09.2026 | Rznomics Reports Major Advances in High-Efficiency Circular RNA Production in Nucleic Acids Research | SEONGNAM, South Korea, Sept. 7, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced a major breakthrough in the high-efficiency production of... |
| 24.08.2026 | Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics | SEONGNAM, South Korea, Aug. 24, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly Gateway Labs (LGL) in San Diego,... |
| 15.06.2026 | Rznomics Presents Clinical Interim Data for RZ-001 in Recurrent Glioblastoma at ASNO 2026 | Dr. Chae-Yong Kim of Seoul National University Bundang Hospital delivers oral presentation on interim data from 10 enrolled patients A manageable safety profile, with prolonged disease control and tumor recurrence inhibition observed in sev... |
| 08.05.2026 | Rznomics Announces U.S. FDA Regenerative Medicine Advanced Therapy Designation Granted to 'RZ-001' for Hepatocellular Carcinoma | RMAT designation based on promising Phase 1b/2a clinical data, including safety profile and preliminary response rates, with trans-splicing ribozyme-based RNA editing platform SEOUL, South Korea, May 8, 2026 /PRNewswire/ -- Rznomics a bioph... |
| 21.04.2026 | Rznomics Reports Interim Clinical Data for RZ-001 in Hepatocellular Carcinoma at AACR 2026 Demonstrating Encouraging Efficacy and Favorable Safety Profile | – RECIST-based ORR of 38.5% (confirmed) and 46.2% (unconfirmed) – mRECIST-based ORR of 61.5% with a complete response (CR) rate of 23% – No Grade 3 or higher adverse events related to RZ-001 observed – Highlights clinical potential of RNA t... |
| - | CEVEC and Rznomics sign license agreement for the use of CAP® Technology in manufacturing of adenoviral vectors | Cologne, Germany and Yongin, Korea, October 19, 2020 - CEVEC Pharmaceuticals GmbH (CEVEC) and Rznomics Inc. (Rznomics) today announced the signing of a clinical and commercial license agreement for the use of CEVEC’s proprietary CAP® Techno... |